Supplemental Table 1: Global Incidence, Prevalence and Mortality in Treated ESKD

Country	Incidence, crude (pmp)	Prevalence, crude (pmp)	Mortality Rate (deaths/100py)	References
Australia[a]	117	988	Early[b]: 25 Late[c]: 14	(1) USRDS, 2018 (2) Robinson, 2014 (3) McDonald, 2015
Argentina	165	872	First year: 18% (adjusted) Annual: 16% (adjusted)	(1) USRDS, 2018 (4) Orias, 2020
Belgium (French sp.)	188	1310	Early: 34 Late: 20	(1) USRDS, 2018 (2) Robinson, 2014
Brazil	194	865	Annual crude mortality 20%	(5) Thomé, 2019 (6) Sesso, 2020
Canada	200	1346	Early: 25 Late: 17	(1) USRDS, 2018 (2) Robinson, 2014
Chile	169	1382	Annual crude mortality 11% (HD), 13% (PD)	(1) USRDS, 2018 (7) Ardiles, 2011
France	165	1278	Early: 23 Late: 16	(1) USRDS, 2018 (2) Robinson, 2014
Germany	65 (excluding transplant[d])	915 (excluding transplant[d])	Early: 20 Late: 15	(2) Robinson, 2014 (8) Scholten, 2019 (9) Potthoff, 2017
Greece	251	1284	ERA-EDTA: 1 and 5-year crude survival 84% and 50%	(1) USRDS, 2018 (10) Kramer, 2019
Guatemala	197	431	_ _	(1) USRDS, 2018
Hong Kong	171	1315	_ _	(1) USRDS, 2018
Italy	145	1150	Early: 28 Late: 13	(1) USRDS, 2018 (2) Robinson, 2014
Japan	296	2599	Early: 17 Late: 5	(1) USRDS, 2018 (2) Robinson, 2014

Kuwait	141	787	_ _	(1) USRDS, 2018
Mexico (Jalisco)	355	1447	11 Among patients initiated on PD	(1) USRDS, 2018 (11) Garcia-Garcia, 2007
Malaysia	259	1352	_ _	(1) USRDS, 2018
Netherlands	117	1047	ERA-EDTA: 1 and 5-year crude survival 84% and 50%	(1) USRDS, 2018 (10) Kramer, 2019
Norway	106	950	ERA-EDTA: 1 and 5-year crude survival 84% and 50%	(1) USRDS, 2018 (10) Kramer, 2019
Romania	175	1038	_ _	(1) USRDS, 2018
Russia	58	303	_ _	(1) USRDS, 2018
Singapore	333	2076	_ _	(1) USRDS, 2018
South Africa	22	181	_ _	(1) USRDS, 2018
South Korea	311	1816	11.6 Among patients on HD or PD for at least 3 months	(1) USRDS, 2018 (12) Kim, 2017
Spain	142	1234	ERA-EDTA: 1 and 5-year crude survival 84% and 50%	(1) USRDS, 2018 (10) Kramer, 2019
Sweden	121	979	Early: 28 Late: 20	(1) USRDS, 2018 (2) Robinson, 2014
Taiwan	493	3392	_ _	(1) USRDS, 2018
Thailand	346	1515	1-year and 5-year PD patient survival: 83% and 54%	(1) USRDS, 2018 (13) Changsirikulchai, 2018
Turkey	140	933	_ _	(1) USRDS, 2018
United Kingdom	120	956	Early: 22 Late: 16	(1) USRDS, 2018 (2) Robinson, 2014
United States	378	2196	Early: 33	(1) USRDS, 2018

			Late: 18	(2) Robinson, 2014

Supplemental Table 2: Global Variation in Kidney Replacement Therapy Modality, by Country and Gross Domestic Product per Capita, in 2016

Country	GDP per Capita, PPP[14]	Dialysis Modality[Fejl! Bogmærke er ikke defineret.]	Kidney Transplant[Fejl! Bogmærke er ikke defineret.]
High Income > $46,647/yr (GDP per Capita, PPP)			
Singapore	$89,228	in-center HD: 72% home HD: 0% PD: 10%	18%
Norway	$58,934	in-center HD: 24% home HD: 0% PD: 5%	70%
United States	$57,928	in-center HD: 63% home HD: 1% PD: 7%	29%
Hong Kong	$57,229	in-center HD: 16% home HD: 2% PD: 44%[a]	38%
Netherlands	$52,283	in-center HD: 30% home HD: 2% PD: 5%	63%
Germany[8,9]	$50,564	HD: 94% PD: 6% (excludes transplant)[b]	--
Sweden	$50,434	in-center HD: 31% home HD: 1% PD: 9%	58%
Taiwan	$49,100	in-center HD: 88% home HD: n/a PD: 8%	4%
Belgium (French sp.)	$48,625	in-center HD: 53% home HD: 1% PD: 4%	41%

Australia	$47,350	in-center HD: 38% home HD: 5% PD: 10%	47%
Upper Middle Income > $15,297/yr (GDP per Capita, PPP)			
Canada	$46,441	in-center HD: 44% home HD: 3% PD: 12%	42%
Kuwait	$44,220	in-center HD: 47% home HD: 0% PD: 7%	46%
United Kingdom	$44,162	in-center HD: 38% home HD: 2% PD: 6%	54%
France	$42,922	in-center HD: 51% home HD: 0% PD: 4%	45%
Japan	$40,004	in-center HD: 95% home HD: 0% PD: 3%	3%
Italy	$39,918	in-center HD: 56% home HD: 0% PD: 7%	37%
South Korea	$37,317	in-center HD: 73% home HD: 0% PD: 7%	19%
Spain	$37,282	in-center HD: 42% home HD: 0% PD: 5%	52%
Greece	$27,823	in-center HD: 76% home HD: n/a PD: 5%	19%
Turkey	$26,329	in-center HD: 75% home HD: 1% PD: 5%	20%
Malaysia	$25,548	in-center HD: 86% home HD: 1%	4%

		PD: 10%	
Romania	$24,316	in-center HD: 85% home HD: 0% PD: 7%	9%
Russia	$24,238	in-center HD: 76% home HD: n/a PD: 5%	19%
Chile	$22,701	in-center HD: 80% home HD: 0% PD: 5%	15%
Argentina	$20,153	in-center HD: 72% home HD: 0% PD: 5%	24%
Mexico (Jalisco)	$19,314	in-center HD: 22% home HD: 0% PD: 35%[c]	44%
Thailand	$16,577	in-center HD: 66% home HD: n/a PD: 26%[d]	8%
Middle Income > $10,482/yr (GDP per Capita, PPP)			
Brazil	$14,255	in-center HD: 66% home HD: 0% PD: 5%	30%
South Africa	$12,588	in-center HD: 73% home HD: n/a PD: 13%	14%
Lower Middle Income > $6,180/yr (GDP per Capita, PPP)			
Guatemala[15]	$8,085	HD: 40% PD: 48%[e]	12%

Supplemental Table Legend

Supplemental Table 1: **Global Incidence, Prevalence and Mortality in Treated ESKD**: Incidence and prevalence data from 2016. Data for Canada exclude Quebec. Data for France exclude Martinique. Data for Guatemala exclude pediatric ESKD patients and patients receiving non-institutional KRT. Data for Italy representative of 35% (7 out of 19 regions) of ESKD patient population. Japan includes dialysis patients only. United Kingdom: England, Wales, Northern Ireland. European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) registries participating in mortality data include Austria, Belgium, Denmark, Finland, France, Greece, Iceland, Norway, Spain, Sweden, the Netherlands, and United Kingdom.

[a] Australia mortality data includes New Zealand.

[b] Early ≤120 days on dialysis.

[c] Late >365 days on dialysis.

[d] Claims data only cover 90% of the German dialysis population, as there are no accessible data on patients with private insurance.

pmp: per million general population. Deaths/100py: deaths per 100 patient-years. HD: hemodialysis. PD: peritoneal dialysis. sp: speaking

Supplemental Table 2: Global Variation in Kidney Replacement Therapy Modality, by Country and Gross Domestic Product per Capita, in 2016. Comparison of gross domestic

product (GDP) per capita, based on purchasing power parity (PPP), to dialysis modality or kidney transplant. Data on 2016 GDP per capita, PPP expressed in international dollars obtained from the World Bank, International Comparison Program database. The income groups are based on GDP per capita, PPP. Dialysis modality and transplant data from USRDS unless otherwise referenced by country. Data for Canada exclude Quebec. Data for France exclude Martinique. Data for Italy representative of 35% (7 out of 19 regions) of ESRD patient population. United Kingdom: England, Wales, Northern Ireland.

[a,c,d,e] Denotes countries with a "PD First" Policy for KRT[16]

[b] Claims data only cover 90% of the German dialysis population, as there are no accessible data on patients with private insurance.

HD: hemodialysis. PD: peritoneal dialysis. sp: speaking

[1] United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.

[2] Robinson BM, Zhang J, Morgenstern H, et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. *Kidney Int*. 2014;85(1):158-165.

[3] McDonald SP. Australia and New Zealand Dialysis and Transplant Registry. *Kidney Int Suppl.* 2015;5(1):39-44.

[4] Orias M, Rosa Diez GJ. Global dialysis perspective: Argentina. *Kidney360.* 2020;1:676-679.

[5] Thomé FS, Sesso RC, Lopes AA, Lugon JR, Martins CT. Brazilian chronic dialysis survey 2017. *J Bras Nefrol*. 2019;41(2):208-214.

[6] Sesso, Ricardo, Lugon JR. Global dialysis perspective: Brazil. *Kidney360*. 2020;1:216-219.

[7] Ardiles LG, Poblete H, Ortiz M, et al. The health system in Chile: the nephrologist perspective. *J Nephrol.* 2011;24(2):149-54.

[8] Scholten N, Ohnhaeuser T, Schellartz I, et al. Multidimensional analysis of factors responsible for the low prevalence of ambulatory peritoneal dialysis in Germany (MAU-PD): a cross-sectional Mixed-Methods Study Protocol. *BMJ Open*. 2019;9(4):e025451.

[9] Potthoff F, Münscher C, Berendes A, *et al*. *Jahresbericht 2016 zur Qualität in der Dialyse*. Münster: MNC, 2017.

[10] Kramer A, Pippias M, Noordzij M, et al. The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary. *Clin Kidney J*. 2019;12(5):702-720.

[11] Garcia-Garcia G, Briseño-Rentería G, Luquín-Arellan VH, et al. Survival among patients with kidney failure in Jalisco, Mexico. *J Am Soc Nephrol.* 2007;18(6):1922-7.

[12] Kim HJ, Park JT, Han SH, et al. The pattern of choosing dialysis modality and related mortality outcomes in Korea: a national population-based study. *Korean J Intern Med*. 2017;32(4):699-710.

[13] Changsirikulchai S, Sriprach S, Thokanit NS, et al. Survival Analysis and Associated Factors in Thai Patients on Peritoneal Dialysis Under the PD-First Policy. *Perit Dial Int*. 2018;38(3):172-178.

[14] World Bank, International Comparison Program database. https://data.worldbank.org/indicator/NY.GDP.PCAP.PP.CD?end=2016&most_recent_year_desc=true&start=1990&view=chart. Accessed 24 June 2020.

[15] Cusumano AM, Garcia-Garcia G, Gonzalez-Bedat MC, et al. Latin American Dialysis and Transplant Registry: 2008 prevalence and incidence of end-stage renal disease and correlation with socioeconomic indexes. *Kidney Int Suppl.* 2013;3(2):153-156.

[16] Abraham G, Varughese S, Mathew M, Vijayan M. A review of acute and chronic peritoneal dialysis in developing countries. *Clin Kidney J*. 2015;8(3):310-7.